Northwest Biotherapeutics Return on Equity

Northwest Biotherapeutics (NWBO) currently reports a ROE of 119.87%. That is above the Healthcare sector average of 22.76%. Use the charts on this page to explore Northwest Biotherapeutics's ROE history and peer comparisons.

Northwest Biotherapeutics's ROE of 119.87% is higher than the Healthcare sector average of 22.76%. That is roughly 426.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Northwest Biotherapeutics's current 119.87% should be judged against Healthcare norms (sector average: 22.76%) and against NWBO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 119.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Northwest Biotherapeutics, and consider following NWBO for alerts when major investors trade the stock.

Northwest Biotherapeutics is classified in the Healthcare sector. On ROE, it currently shows 119.87% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NWBO with unrelated industries.